You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 160 No. 17, September 25, 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Commentary
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Quality of Care
 •Evidence-Based Medicine
 •Statistics and Research Methods
 •Randomized Controlled Trial
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

National Guidelines, Clinical Trials, and Quality of Evidence

Arch Intern Med. 2000;160:2577-2580.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INTRODUCTION

THE RESULTS of clinical trials provide the best evidence for clinical decision making and public policy. Since the publication of a meta-analysis showing the benefits of low-dose diuretic therapy for the treatment of hypertension,1 several new clinical trials have been published, and their results are being incorporated into the new guidelines for hypertension. Both the British and American hypertension guidelines2-3 recommend not only low-dose diuretics but also dihydropyridine calcium channel blockers for older adults with isolated systolic hypertension on the basis of the results of the Systolic Hypertension in Europe Trial (Syst-Eur Trial).4 In the new British Hypertension Society guidelines for hypertension management,2 the authors rely on evidence from the Hypertension Optimal Treatment randomized trial (HOT)5 to define treatment goals. Moser's6 review of the national recommendations for the pharmacologic treatment of hypertension considers the recently published Captopril Prevention Project (CAPPP) randomized trial.7

Confidence in the findings of randomized clinical trials . . . [Full Text of this Article]

ADEQUATE RANDOMIZATION

BLINDING

EVENTS ASCERTAINMENT

GENERALIZABILITY



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Management of Hypertension in Patients with Type 2 Diabetes Mellitus: Guidelines Based on Current Evidence
Kaplan
ANN INTERN MED 2001;135:1079-1083.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.